Focused Radiation Plus a Targeted Drug for HER2 Positive Breast Cancer in the Brain
Original title: Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test of the two together in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a targeted drug given with focused radiation for breast cancer that has spread to the brain.
Who this trial is for. This trial is for people with HER2 positive breast cancer that has spread to the brain. It tests a drug called trastuzumab deruxtecan given with focused radiation, known as stereotactic radiosurgery: Radiation aimed at a small target, in one visit or a few. There is no cutting, despite the name. See the glossary.
Where it stands. The trial has not reported results. It is looking at how well brain tumors can be controlled when the drug and the focused radiation are used together. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Using these two together is still being studied, so it is not standard care. Someone whose cancer fits this picture could ask their care team about it.
What it doesn't mean: This does not mean the combination works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.